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Abstract: Aspergillus fumigatus is a serious cause of disease in immune-deficient patients and in
those with pulmonary malfunction (e.g., cystic fibrosis (CF), asthma). Atorvastatin is a member
of the statin drug family, which are the main therapeutic agents used to decrease high serum
cholesterol levels by inhibiting (HMG-CoA) reductase enzyme. The aim of the work presented
here was to analyse the antifungal activity of atorvastatin and assess its effect on the virulence of
A. fumigatus. Atorvastatin demonstrated strong antifungal activity and reduced the growth and
viability of A. fumigatus. Exposure of A. fumigatus to atorvastatin led to a reduction in ergosterol
content and increased membrane permeability, as evidenced by the release of protein, amino acids
and gliotoxin. Proteomic analysis revealed an increased abundance of proteins associated with an
oxidative stress response, such as the glutathione s-transferase family protein (+8.43-fold), heat
shock protein Hsp30/Hsp42 (+2.02-fold) and 5-demethoxyubiquinone hydroxylase, mitochondrial
(+1.73-fold), as well as secondary metabolites such as isocyanide synthase A icsA (+8.52-fold)
and non-ribosomal peptide synthetase fmpE (+3.06-fold). The results presented here indicate that
atorvastatin has strong antifungal properties and may have potential application in the treatment of
A. fumigatus infections alone or in combination with existing antifungal agents.
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1. Introduction
Aspergillus fumigatus is a serious cause of disease in immunocompromised patients or in those
with pulmonary malfunction. A. fumigatus is widely distributed in the environment and produces
large numbers of conidia [1,2], which are inhaled on a daily basis. A rapid immune response eliminates
these in the immunocompetent host but in cases of pulmonary disease (e.g., cystic fibrosis (CF), asthma)
or immunosuppression conidia can quickly germinate and grow in the lung [1,3]. The fungus can
cause three types of disease. Saprophytic infection involves the growth of the fungus in the lung and is
seen in asthmatic and CF patients [4]. Allergic bronchopulmonary aspergillosis occurs when the body
reacts to toxins and allergens secreted by the fungus as it grows in the thick mucus secretion found in
the CF or asthmatic lung. Invasive aspergillosis occurs in immunocompromised patients and involves
the fungus growing through viable tissue and disseminating to other sites in the body [5]. Invasive
aspergillosis can have a mortality rate of 80%–90% and is difficult to diagnose and treat [6]
A. fumigatus displays a number of characteristics that facilitate its growth and persistence in
the lung. The fungus is thermotolerant and can survive temperatures up to 45 ◦C [7]. It is capable
of producing a wide range of enzymes that may facilitate the degradation of tissue and toxins (e.g.,
gliotoxin, fumagillin), which may play a role in suppressing the local immune response [8,9].
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Treatment of aspergillosis involves the use of a range of antifungal drugs. Azole antifungal agents,
such as voriconazole, show efficacy against invasive aspergillosis. The polyene Amphotericin B has
been widely used for the treatment of invasive aspergillosis and, due to its inherent toxicity, is now
usually administered in a liposomal formulation [10,11]. Echinocandins, such as caspofungin, show
good efficacy against aspergillosis and are well tolerated in vivo [12].
Statins are widely used for the control of cholesterol and act by inhibiting the action of
3-hydroxy-3-methylglutaryl-CoA (HMG-Co A) reductase and thus block cholesterol biosynthesis [13,14].
Statins may be produced naturally (e.g., lovastatin), semi-synthetically (e.g., simvastatin) or synthetically
(e.g., atorvastatin) and were originally obtained from a variety of fungi (e.g., Aspergillus terreus,
Penicillium citrinum) [14]. Mammalian cholesterol and fungal ergosterol are structurally similar and
their biosynthetic pathways are closely related [14]. Consequently, fungal cells exposed to statins show
reduced ergosterol content [15]. Statins have well-established antifungal properties and have been
shown to inhibit the growth of a wide range of filamentous fungi (e.g., A. fumigatus, Aspergillus flavus,
Aspergillus terreus, and Aspergillus niger) [16] and yeasts [15]. Exposure of Candida glabrata to simvastatin
resulted in inhibition of growth, reduced levels of ergosterol and disruption of mitochondrial DNA [17].
Statins can exhibit fungicidal properties but only at concentrations in excess of those that can be
clinically achieved [16]. It has been reported that patients on high doses of statins show fewer fungal
infections [18–20], prompting the suggestion that statins may represent a well-tolerated antifungal
therapy that could be used alone or in combination with conventional therapies for the treatment of
recalcitrant infections [21].
The aim of the work presented here was to characterize the response of A. fumigatus to one of
the most widely prescribed statins, atorvastatin, with a view to determining its potential as a novel
antifungal therapy.
2. Materials and Methods
2.1. Aspergillus Isolates
Conidia of A. fumigatus ATCC 26,933 were isolated from malt extract agar (MEA) plates using
PBS-Tween (PBS +0.5% (v/v) Tween 80) and harvested by centrifugation (2056× g) for 10 min.
The conidial pellet was washed twice with 5 mL PBS and resuspended in SAB liquid medium at a
concentration of 5 × 106/mL.
2.2. Statin
Tablets of atorvastatin (20 mg Film-Coated Rowex Ltd) were crushed to a powder and dissolved
in sterile PBS. The solution was filtered sterilised using 0.45 µm and 0.02 µm pore filters.
2.3. Susceptibility of A. fumigatus to Atorvastatin
The conidia suspension (100 µL) was added to each well of a 96-well plate containing serial
dilutions of atorvastatin in 100 µL of Sabouraud Dextrose Broth. The plate was incubated at 37 ◦C for
48 h. The optical density at 600nm was determined using a microplate reader (Synergy HT, Bio-Tek)
and growth was quantified as a percentage of control.
2.4. Effect of Atorvastatin on A. fumigatus on Biomass Production
Cultures A. fumigatus were grown on MEA plates for 3–4 days at 37 ◦C and the conidia were
harvested using sterile 0.5% (v/v) Tween 80. The concentration of conidia was adjusted to 5 × 106
conidia/mL in sterile PBS. This conidial suspension was used to inoculate 100 mL Sabouraud dextrose
broth supplemented with atorvastatin (1.5 and 6 µg/mL). The culture was incubated at 37 ◦C in a
shaking incubator at 200 rpm for 72 h and the fungal hyphae were weighed after collection by filtering
through miracloth (Calbiochem) and exclusion of remaining culture medium.
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2.5. Ergosterol Extraction and Quantification
Ergosterol was extracted from 1 g A. fumigatus mycelium as described in [22]. Ergosterol
quantification was performed using a gas chromatograph (Hewlett Packard 5890 series II) with a flame
ionization detector and a chrompack capillary column (Chrompack International BV, Middleburg,
The Netherlands). The carrier gas was N2, and the injector and detector temperatures were set at
320 ◦C. Ergosterol standards were used to calibrate the instrument.
2.6. Determination of Amino Acid and Protein Leakage
A. fumigatus was grown for 72 h and exposed to atorvastatin (1.5, 3 and 6 µg/mL) for 2, 4 and 6 h
at 37 ◦C. The release of amino acids was determined using the ninhydrin colorimetric method and
expressed in terms of aspartic acid and glutamic acid [23]. Ninhydrin (Sigma-Aldrich) was dissolved
in ethanol to give a final concentration of 0.35% (w/v) and 200 µL was added to each sample (1 mL)
and heated to 95 ◦C for 4 min followed by cooling on ice. The absorbance at 600 nm was recorded on
a spectrophotometer (Beckman DU 640 Spectrophotometer). The quantity of protein released from
the hyphae in the supernatant was assayed using the Bradford assay (Bio-Rad), with bovine serum
albumin (BSA) (Sigma-Aldrich) as standard.
2.7. Gliotoxin Extraction and Qquantification
Seventy-two hours A. fumigatus cultures were harvested by filtration using miracloth. Chloroform
(20 mL) were added to an equal volume of each filtrate sample and the solution was mixed continually
for 2 h. The chloroform was evaporated to dryness in a rotary evaporator. Dried extracts were
dissolved in 500 µL methanol (Fisher chemical) and stored at -20 ◦C until assayed. Gliotoxin was
determined by reverse-phase HPLC (Agilent 1200 Series). The mobile phase was acetonitrile (Fisher
chemical), 0.1% (v/v) trifluoroacetic acid (Sigma-Aldrich) and deionized-distilled water. Gliotoxin
extract (20 µL) was injected onto a C18 Hewlett Packard column. Gliotoxin concentrations (50, 100 and
200 ng/mL) were dissolved in methanol (Sigma-Aldrich) to create a standard curve of peak area versus
gliotoxin concentration.
2.8. Protein Extraction and Preparation for Label-Free Mass Spectrometry Analysis
Label-free shotgun semi-quantitative proteomics was conducted on A fumigatus hyphae pre-grown
in the presence of atorvastatin (3 µg/mL) for 72 hours. Protein was extracted as described by [24].
Briefly, protein (75 µg) was reduced with dithiothreitol (DTT; 200 mM) (Sigma-Aldrich), alkylated
with iodoacetamide (IAA; 1 M) (Sigma-Aldrich) and digested with sequence grade trypsin (Promega,
Ireland) at a trypsin:protein ratio of 1:40, overnight, at 37 ◦C. Tryptic peptides were purified for mass
spectrometry using C18 spin filters (Medical Supply Company, Ireland) and 1 µg of peptide mix was
eluted onto a Q-Exactive (ThermoFisher Scientific, U.S.A) high resolution accurate mass spectrometer
connected to a Dionex Ultimate 3000 (RSLCnano) chromatography system. Peptides were separated by
an increasing acetonitrile gradient on a Biobasic C18 Picofrit™ column (100 mm length, 75 mm ID),
using a 65 min reverse-phase gradient at a flow rate of 250 nL/min. All data were acquired with the mass
spectrometer operating in an automatic data-dependent switching mode. A high-resolution MS scan
(300–2000 Dalton) was performed using the Orbitrap to select the 15 most intense ions prior to MS/MS.
2.9. Protein Data and Analysis
Protein identification from the MS/MS data was performed using the Andromeda search engine
in MaxQuant (version 1.2.2.5; http://maxquant.org/) to correlate the data against the proteome of A.
fumigatus obtained from Uniport. The following search parameters were used: first search peptide
tolerance of 20 ppm and second search peptide tolerance of 4.5 ppm, with carbamidomethylation of the
cysteines set as a fixed modification, while oxidation of methionines and acetylation of N-terminals were
set as variable modifications and a maximum of 2 missed cleavage sites allowed. False Discovery Rates
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(FDR) were set to 1% for both peptides and proteins and the FDR was estimated following searches
against a target-decoy database. Peptides with minimum length of seven amino acid length were
considered for identification and proteins were only considered identified when more than one unique
peptide for each protein was observed. Results processing, statistical analyses and graphics generation
were conducted using Perseus v. 1.5.5.3. LFQ intensities were log2-transformed and ANOVA and t-tests
between the proteome of 24-h control and atorvastatin-treated (3 µg/mL) A fumigatus was performed
using a p-value of 0.05 and significance was determined using FDR correction (Benjamini–Hochberg).
Proteins that had non-existent values (indicative of absence or very low abundance in a sample) were
also used in statistical analysis of the total differentially expressed group following imputation of the
zero values using a number close to the lowest value of the range of proteins plus or minus the standard
deviation. After data imputation these proteins were included in subsequent statistical analysis. The
Blast2GO software was applied to determine gene ontology terms (GO terms) relating to biological
processes (BP) and molecular function (MF).
2.10. Statistical Analysis
Results presented in this paper are the mean of at least two independent determinations and
the results are presented as the mean ± standard error. Experimental data were tested for statistical
significance using a Student’s t-test. For all experimentation a p-value of ≤0.05 was considered
statistically significant All the statistical analyses listed were performed using GraphPad Prism.
2.11. Data Availability
The MS proteomics data and MaxQuant search output files have been deposited to the
ProteomeXchange Consortium [25] via the PRIDE partner repository with the dataset identifier PXD015254.
3. Results
3.1. Effect of Atorvastatin on Growth of A. fumigatus
Exposure of A. fumigatus conidia (initial density 1 × 106/mL) to atorvastatin for 48 h at 37 ◦C
resulted in reduced growth. An atorvastatin dose of 6.25 µg/mL inhibited growth by 86.4% ± 2.7%
(p < 0.0001) while doses of 3.12 and 1.56 µg/mL reduced growth by 83% ± 2% and 47.6% ± 4.7%
(p < 0.002), respectively, at the same timepoint (Figure 1). Exposure of cultures of A. fumigatus to
atorvastatin lead to a significant inhibition in biomass accumulation at 72 h. Cultures were pre-grown
for 24 h and then supplemented with atorvastatin at the concentrations stated for a further 48 h.
Biomass was reduced from 3.45 ± 0.13 g/100 mL in control cultures to 2.28 ± 0.08 g/100 mL (p = 0.0018)
at an atorvastatin concentration of 1.5 µg/mL and at a concentration of 6 µg/mL biomass was reduced
to 0.488 ± 0.04 g/100 mL (p < 0.0001) (Figure S1). Incorporation of atorvastatin into malt extract agar
also led to a reduction in growth of A. fumigatus colonies (Figure S2).
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Figure 1. Effect of atorvastatin on growth of A fumigatus. A. fumigatus conidia (initial concentration 1 
x 106/mL) were exposed to atorvastatin in SAB culture medium. Growth (%) was calculated by 
comparing atorvastatin-treated A. fumigatus to control cells after 48 h growth (** p < 0.01; *** p < 0.001). 
Figure 1. Effect of atorvastatin on growth of A fumigatus. A. fumigatus conidia (initial concentration
1 × 106/mL) were exposed to atorvastatin in SAB culture medium. Growth (%) was calculated by
comparing atorvastatin-treated A. fumigatus to control cells after 48 h growth (** p < 0.01; *** p < 0.001).
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3.2. Measurement of Ergosterol from A. fumigatus Mycelium Exposed to Atorvastatin
Ergosterol was extracted from mycelial exposed to atorvastatin as described and quantified by
GC analysis. Exposure of A. fumigatus cultures to atorvastatin (3 µg/mL) for 72 h lead to a significant
reduction in ergosterol production (Figure 2) (control = 0.088 ± 0.008 mg/g and atorvastatin-treated
mycelia = 0.006 ± 0.0012 mg/g (p < 0.01).
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Figure 2. Atorvastatin (3 µg/mL) exposure reduced the ergosterol content of A. fumigatus. Ergosterol
quantification was performed using a gas chromatograph with a flame ionization detector and a
chrompack capillary colu n. Ergosterol standards were used to calibrate the instrument. Ergosterol
content was expressed in terms of mg/mL (** p < 0.01).
3.3. Atorvastatin Induces Leakage from A. fumigatus
The effect of atorvastatin on membrane permeability was assessed by quantifying amino acid,
protein and gliotoxin release from cells. Exposure of A. fumigatus hyphae to atorvastatin (3 µg/mL) for
4 or 6 h led to an increase in amino acid release from cells (Figure 3A). At 4 h amino acid release from
control cells was 0.14 ± 0.0035 µg/mL but in the 3 µg/ L atorvastatin treatment it was 0.5 ± 0.0037
µg/ L (p < 0.0001). At 6 h exposure the amino acid release from control cells was 0.4 ± 0.004 µg/mL and
1.08 ± 0.04 µg/mL (p < 0.0001) from the cells supplemented with the 3 µg/mL atorvastatin. Exposure of
A. fumigatus to atorvastatin also led to increased protein leakage (Figure 3B). Exposure to atorvastatin
for 4 h lead to a protein c ncentration of 107.6 ± 5.2 µg/mL in the 3 µg/mL treatment compared to
85.6 ± 6 µg/mL in t e control, and after 6 h in contr l the protein release was 106.8 ± 3.1 µg/mL
co are to 150.5 ± 3.6 µg/mL in the treatment (3 µg/mL) (p < 0.02).
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Figure 3. Effect of atorvastatin on the release of amino acids (a) and protein (b) from A. fumigatus.
The effect of atorvastatin (3 µg/mL) on A. fumigatus amino acid and protein release was determined by a
ninhydrin colorimetric assay and Bradford protein assay, respectively. Atorvastatin treatment resulted
in increased amino acid and protein rele se relative to control cells (* p < 0.05; ** p < 0.01; *** p < 0.001).
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Atorvastatin exposure also induced an increase in the release of gliotoxin from A. fumigatus
cultures (Figure 4). After 72 h growth at 37 ◦C gliotoxin was 14.04 ± 1.01 ng/mL at an atorvastatin
concentration of 1.5 µg/mL compared to the control, which was 4.2 ± 0.6 ng/mL (p = 0.005). At an
atorvastatin concentration of 6 µg/mL the gliotoxin concentration was 47.22 ± 5.06 ng/mL (p = 0.01).
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Figure 4. Atorvastatin exposure increased the gliotoxin release from A. fumigatus. Gliotoxin
quantification was performed using an HPLC. The gliotoxin standards were used to calibrate the
instrument. Gliotoxin content was expressed in terms of ng/mL (* p < 0.01; ** p < 0.01).
3.4. Proteomic Analysis of Response of A. fumigatus to Atorvastatin
Proteomic analysis of A. fumigatus cultures exposed to atorvastatin revealed 25,915 peptides
representing 1360 proteins, and 128 proteins were determined to be differently abundant with a
fold change of >1.5. In total 83 proteins were increased in abundance and 45 were decreased in
abundance. These proteins were subsequently used to statistically analyse the total differentially
expressed group after imputation of the zero values as described and were then included in statistical
analysis after data imputation. A principal component analysis (PCA) was performed on all filtered
proteins and clearly distinguished the control and atorvastatin treated A. fumigatus samples (Figure S3).
The volcano plot shows the relative distribution of these proteins (Figure 5), and of the proteins that
increased in abundance following exposure to atorvastatin, the most notable were isocyanide synthase
A (+8.52-fold), glutathione S-transferase family protein (+8.43-fold), kynureninase 2 (+4.48-fold), and
non-ribosomal peptide synthetase fmpE (+3.06-fold). The main peptides decreased in abundance were
O-methyltransferase (-3.68-fold), allergen Asp f 15 (-2.45-fold) and GNAT family acetyltransferase
(-2.25-fold).
The main enzyme classes that were altered in abundance in A. fumigatus treated with atorvastatin
were oxidoreductases, transferases and hydrolases (Figure S4). Oxidoreductase enzymes that increased
in abundance in atorvastatin treatment of A fumigatus were pyoverdine/dityrosine biosynthesis
family protein (+8.52-fold), 5-demethoxyubiquinone hydroxylase, mitochondrial (+1.73-fold), alcohol
dehydrogenase, putative (+1.6-fold) and Psi-producing oxygenase A (+1.55-fold). Thirteen
oxidoreductase enzymes showed a decrease in abundance and included aflatoxin B1-aldehyde
reductase GliO-like, putative (−2.86-fold), aryl-alcohol dehydrogenase, putative (−1.52-fold)
and NADH-dependent flavin oxidoreductase, putative (−1.50-fold). Enzymes with transferase
activity increased in abundance included glutathione S-transferase family protein (+8.43-fold),
phosphatidylinositol transporter, putative (+2.00-fold) and allergen Asp f 4 (+1.42-fold), while
O-methyltransferase (−3.68-fold), malate synthase (−2.40-fold) and GNAT family acetyltransferase,
putative (−2.25-fold) were decreased in abundance. Nine hydrolytic enzymes were increased in
abundance and these included kynureninase (4.48-fold), amidase putative (+2.77-fold), lipase/esterase
putative (+2.12-fold) and methionine aminopeptidase 2-2 (+1.83-fold). In contrast two hydrolytic
enzymes were reduced in abundance (haloalkanoic acid dehalogenase, putative (−2.99-fold) and
phytase, putative (−1.42-fold).
J. Fungi 2020, 6, 42 7 of 10
J. Fungi 2020, 6, x FOR PEER REVIEW 7 of 10 
 
 
Figure 5. Volcano plot showing the distribution of quantified proteins according to p value (−log10 p-
value) and fold change (log2 mean LFQ intensity difference). Proteins above the horizontal line are 
considered statistically significant (p value < 0.05) and those to the right and left of the vertical lines 
indicate relative fold changes of ±1.5. 
4. Discussion 
Statins are widely used for the control of cholesterol and function by inhibiting the action of 3-
hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase [26,27]. Patients on statin therapy display 
lower incidences of fungal infections [19,28], prompting the suggestion that statins may display a 
significant antifungal effect [20] and could have applications in treating recalcitrant fungal infections. 
Statins can inhibit the growth of C. albicans [15] and growth inhibition may be via a reduction in 
ergosterol content [29]. High dose of statin treatment has been correlated with immune-modulatory 
effects in some patients [30,31] and, in particular, the induction of modulation in the activity of 
regulatory T cells [32]. 
Exposure of A. fumigatus to atorvastatin reduced fungal growth and induced increased 
membrane permeability as evidenced by increased release of protein and amino acids. Maximum 
amino acid and protein leakage occurred in the 3 μg/mL treatment at 6 h and this concentration may 
be optimal for this effect. Statins inhibit the production of cholesterol in mammals and have 
previously been shown to inhibit ergosterol biosynthesis in fungi [29]. Reduced ergosterol in 
atorvastatin-treated A. fumigatus cells may alter the integrity of the membrane and thus lead to 
increased permeability. Cultures treated with atorvastatin also released elevated levels of gliotoxin, 
which also has been observed in A. fumigatus exposed to amphotericin B and may indicate an 
oxidative stress response [33]. 
Proteomic analysis revealed an increased abundance of a range of proteins involved in dealing 
with oxidative stress, including pyoverdine/dityrosine biosynthesis (+8.52-fold), 5-
demethoxyubiquinone hydroxylase, mitochondrial (+1.74-fold) and alcohol dehydrogenase (+1.61-
fold). In Saccharomyces cerevisiae, dityrosine is a major component of the spore wall surface and plays 
a role in the resistance of ascospores to environmental stress [34]. Furthermore, the glutathione S-
transferase family protein is increased in abundance (+8.43-fold), and this protein functions to 
detoxify xenobiotics. The fumipyrrole biosynthetic (fmpE) protein was also increased in abundance 
(+3.06-fold). Deletion of fmpE in A. fumigatus resulted in reduced growth and sporulation of the 
Figure 5. Volcano plot showing the distribution of quantified proteins according to p value (−log10
p-value) and fold change (log2 mean LFQ intensity difference). Proteins above the horizontal line are
considered statistically significant (p value < 0.05) and those to the right and left of the vertical lines
indicate relative fold changes of ±1.5.
4. Discussion
Statins are widely used for the control of cholesterol and function by inhibiting the action of
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductas [26,27]. Patients on statin therapy display
lower incidences of fung l infections [19,28], prompting the suggestion that statins may display a
significant antifungal effect [20] and c uld have a plicatio s in treating recalcitrant fu gal infections.
Stat ns can inhib t the growth of C. albicans [15] and growth inhibitio may be via a reduction in
ergosterol o tent [29]. Hi h dose f statin treatment has been correlated with immune-modulatory
effects in s me patients [30,31] and, in particul r, the induction f modulat on in the activity of
regulatory T cells [32].
Exposure of A. fumigatus to atorvastatin reduced fungal growth and induced increased membrane
permeability as evidenced by ncreased release of protein and ami o acids. Maximum amino ac d and
protein leakage occurred n the 3 µg/mL treatment at 6 h and this concentratio m y be opt mal for this
effect. Statins inhibit th production of cholesterol in mammals and h ve previously been shown to
inhibit ergosterol biosynth sis in fu gi [29]. Reduced ergosterol in at rvastatin-treated A. fumigatus
cells may alter the integrity of the membrane and thus lead to increased permeability. Cultures treated
with atorvas atin also released elevated levels of gliotoxin, which also has been observed i A. fumigatus
exposed to amphotericin B and may indicate an oxidative s ress response [33].
Proteomic analysis revealed an increased abundance f a range of r ins i volve in deali g with
oxidative stress, including pyoverdine/dityrosine biosynthesis (+8.52-fold), 5-demethoxyubiquinone
hydroxylase, mitochondrial (+1.74-fold) and alcohol dehydr genase (+1.61-fold). I Saccharomyces
cerevisiae, dityrosine is a major component of the spo e wall surface and plays a role in the resistance of
ascospores to environmental stress [34]. Furthermo e, the glutathione S-transferas family prot in is
increased in abundance (+8.43-fold) and this protein functions to d toxify x nobiotics. The fumipyrrole
biosynthetic (fmpE) protein was also increased i abundance (+3.06-fold). Del tion of fmpE in
A. fumigatus resulted in educed growth and sporulatio of the mutant strains but virule ce was not
alter d as compared to the WT strain in a murine infection model [35].
A range of heat shock proteins, such as Hsp30/H p42 (+2.02-fold), also increase in ab ndance in
response to atorvastatin. Heat shock proteins play an important role in adaptation of the fungal cell to
environmental and chemical stresses [36]. A. fumigatus heat shock proteins are also immunodominant
and elicit strong humoral immune responses [37]. Proteomic analysis also revealed the reduced
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abundance of a number of peptides associated with virulence, including aflatoxin B1 (−2.86-fold) and
allergen Asp f 15 (−2.45-fold). Asp f 15 is cell-wall associated and its decreased abundance could be
due to an altered cell-wall composition as a result of an altered membrane composition.
Statins inhibit the growth of A. fumigatus and supplementation of media with ergosterol or
cholesterol blocked the growth-inhibiting effect of atorvastatin, thus indicating the specificity of statins
for the mevalonate synthesis pathway [15]. However, another study found that statins were fungistatic
against A. fumigatus, but the MICs were greater than the clinically achievable concentrations [16].
Furthermore, a variety of Candida strains that were resistant to fluconazole and nystatin were all
sensitive to atorvastatin [38]. Atorvastatin combined with fluconazole improved cryptococcosis caused
by Cryptococcus gattii and mice treated with atorvastatin had increased survival and better clinical
outcomes; this was mediated via modifications in the capsule and cell membrane in the presence of a
statin that induced cell death within phagocytes [39].
5. Conclusions
The results presented here confirm previous findings obtained using statins (e.g., a reduction in
ergosterol content); however, the alteration in membrane permeability caused by atorvastatin and
the altered proteomic response are indicative of oxidative stress in the cells. Fully understanding the
antifungal mode of action of statins may highlight novel ways to utilise these widely used drugs for
the control of recalcitrant fungal infections.
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Figure S1. The biomass of A. fumigatus exposed to atorvastatin (1.5 and 6 µg/mL). Figure S2: Growth area of A.
fumigatus on MEA plates supplemented with atorvastatin. Figure S3. Principal component analysis of control and
atorvastatin treated A. fumigatus at 24 h showing a clear distinction between control and treatment. Figure S4.
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assigned groups based on involvement in biological processes for control and atorvastatin treated.
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